HP and gastric cancer: Japan has demonstrated the effectiveness of risk stratification for GC using a serum screening system, including a serum pepsinogen (PG) series with or without an anti-HP antibody (HPIgG) [10,11,12,13], to address the lack of EGD processing capacity.